Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Odin

Showing results (61-70 of 170) with videos related to

Pageof 17
Sort By:
NPJ Parkinson'S Disease|June 2, 2022
Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinson's diseaseMatthias Löhle, Alexander Bremer, Florin Gandor, et al.
BMJ Neurology Open|May 7, 2026
Suicidal behaviour and suicide mortality in Parkinson's disease: a nationwide register-based cohort studySara Lindström, Mirjam Wolfschlag, Gustav Cedergren Weber, et al.
Neurology and Therapy|June 10, 2025
Levodopa Intestinal Gel Infusion Therapies in Advanced Parkinson's Disease: A Swedish Study on Real-World Use and CostsPer Odin, Christoffer Tærud, Jenny Samuelsson, et al.
The AAPS Journal|December 12, 2012
Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patientsDag Nyholm, Per Odin, Anders Johansson, et al.
NPJ Parkinson'S Disease|December 20, 2018
Reduced workforce participation 5 years prior to first Parkinson's disease sick-leaveJonathan Timpka, Örjan Dahlström, Armin Spreco, et al.
NPJ Parkinson'S Disease|February 2, 2018
Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristicsDavid G Standaert, James T Boyd, Per Odin, et al.
NPJ Parkinson'S Disease|July 21, 2017
Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the futureK Ray Chaudhuri, Mubasher A Qamar, Thadshani Rajah, et al.
Journal of Neurology|January 29, 2005
Is levodopa toxic?Thomas Müller, Harald Hefter, Roland Hueber, et al.
Clinical Neuropharmacology|June 4, 2008
Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complicationsKarla Eggert, Christoph Schrader, Michaela Hahn, et al.
Scientific Reports|January 12, 2022
Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson's diseaseLars Lau Raket, Daniel Oudin Åström, Jenny M Norlin, et al.
Pageof 17

Showing results (61-70 of 170) with videos related to

Sort By:
Pageof 17
NPJ Parkinson'S Disease|June 2, 2022
Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinson's diseaseMatthias Löhle, Alexander Bremer, Florin Gandor, et al.
BMJ Neurology Open|May 7, 2026
Suicidal behaviour and suicide mortality in Parkinson's disease: a nationwide register-based cohort studySara Lindström, Mirjam Wolfschlag, Gustav Cedergren Weber, et al.
Neurology and Therapy|June 10, 2025
Levodopa Intestinal Gel Infusion Therapies in Advanced Parkinson's Disease: A Swedish Study on Real-World Use and CostsPer Odin, Christoffer Tærud, Jenny Samuelsson, et al.
The AAPS Journal|December 12, 2012
Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patientsDag Nyholm, Per Odin, Anders Johansson, et al.
NPJ Parkinson'S Disease|December 20, 2018
Reduced workforce participation 5 years prior to first Parkinson's disease sick-leaveJonathan Timpka, Örjan Dahlström, Armin Spreco, et al.
NPJ Parkinson'S Disease|February 2, 2018
Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristicsDavid G Standaert, James T Boyd, Per Odin, et al.
NPJ Parkinson'S Disease|July 21, 2017
Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the futureK Ray Chaudhuri, Mubasher A Qamar, Thadshani Rajah, et al.
Journal of Neurology|January 29, 2005
Is levodopa toxic?Thomas Müller, Harald Hefter, Roland Hueber, et al.
Clinical Neuropharmacology|June 4, 2008
Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complicationsKarla Eggert, Christoph Schrader, Michaela Hahn, et al.
Scientific Reports|January 12, 2022
Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson's diseaseLars Lau Raket, Daniel Oudin Åström, Jenny M Norlin, et al.
Pageof 17